PROCEPT BioRobotics stock gains 3.92 percent as lawsuit risk lingers

Published on 10/05/2026 at 21:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PROCEPT BioRobotics stock faces a securities lawsuit announced October 1 over alleged discounting practices. Q2 revenue reached USD 94.5 million, while the adjusted loss was USD 0.47 per share.

PRCT, US74276L1052, Illustration mit AI erstellt.

PROCEPT BioRobotics stock (ISIN US74276L1052) was trading at USD 17.83 on Nasdaq on October 5, 2026, up 3.92 percent, as a securities lawsuit kept attention on the companys sales practices. The complaint, announced by PR Newswire on October 1, alleges that a discount program encouraged bulk orders above procedure demand and contributed to excess handpiece inventory.

Lawsuit centers on handpiece demand

The allegations concern the reliability of reported U.S. handpiece sales and the risk that customer orders did not fully reflect underlying procedure demand. The filing is an allegation, not a court finding, but it adds a legal dimension to the operational questions already surrounding PROCEPTs growth model.

PROCEPT BioRobotics describes itself as a commercial-stage surgical robotics company focused on urology. Its AQUABEAM Robotic System initially targets benign prostatic hyperplasia, giving the sales debate a direct connection to the companys core product.

Revenue grows while losses persist

In Q2 2026, revenue reached USD 94.5 million, an increase of 19.3 percent from the year-earlier quarter, while the adjusted loss was USD 0.47 per share. MarketBeat reported that revenue exceeded the USD 92.77 million consensus estimate, while the loss missed the USD 0.46 estimate by USD 0.01.

The contrast matters for investors: sales growth remains measurable, but profitability and demand quality remain central tests for the business. MarketBeat reported a Hold consensus from 15 analysts and an average 12-month price target of USD 25.09, placing the target 40.9 percent above the October 5 trading price.

Stock remains near yearly low

PROCEPT BioRobotics had a market capitalization of USD 1.0 billion and traded within a 52-week range of USD 16.66 to USD 38.11 on October 5, 2026. Volume stood at 567,001 shares, while the October 5 price was 53.2 percent below the 52-week high.